Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Aktiespararna Sedermeradagen (May 2019)
20 slides from Cantargia Ab's conference presentation, May 20, 2019
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Liselotte Larsson, VP Operations 1
Slide 2: Safe Harbour Statement
Safe Harbour Statement The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia’s current thinking with respect to future
Slide 3: ASCO oral presentation of CANFOUR phase I data
ASCO oral presentation of CANFOUR phase I data June 2 at 08.00-11.00 in Category: Developmental Immunotherapy and Tumor Immunobiology “Results from a first-in-man, open label, safety and tolerability trial of CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor targ
Slide 4: Cantargia – opportunity to save lives and create value
Cantargia – opportunity to save lives and create value • Potentially more effective treatments in clinically validated pathway • First in class platform technology against novel target • Right team and clear plan to position our projects and maximize value 4
Slide 5: Cantargia core – counteracting tumor inflammation
Cantargia core – counteracting tumor inflammation Intrinsic pathway CANCER Immune suppression Genome instability Tumor-promoting and mutation inflammation Mestatases Resistance to therapy Extrinsic pathway 5
Slide 6: Clinical validation of inflammation pathway
Clinical validation of inflammation pathway CANTOS trial (n=10 061) Canakinumab phase 3 trials (to be completed 2021/2022) • Canakinumab anti IL-1β (Novartis) • Reduced lung cancer incidence by 67 % and Adjuvant NSCLC (CANOPY-A) 1500 patients death by 77 %. After surgery, no mets, placebo control Fi
Slide 7: CAN04 (nidanilimab) added value vs canakinumab
CAN04 (nidanilimab) added value vs canakinumab Canakinumab • Antibody directed against one of the two IL-1 ligands, IL-1β CAN04 (nidanilimab) Double mechanism • Binds the signalling receptor and counteracts both ligands • Induces killing via the immune system (ADCC) IL-1 signalling …..Cantargia has
Slide 8: CAN04 – Dual anticancer mechanism
CAN04 –Dual anticancer mechanism NSCLC Blocking IL-1 signaling 3F8 mIgG, Ligand hIL-1a 3F8 mIgG, Ligand hIL-1b 100 90 90 80 IL1α 80 IL-1α IL-1β 70 70 60 % Inhibition % Inhibition 60 50 50 40 40 30 30 20 20 10 10 0 0 0.01 1 100 0.01 1 100 Concentration (nM) Concentration (nM) IL1β ADCC CAN04 Control
Slide 9: CAN04 – CANFOUR clinical trial
CAN04 – CANFOUR clinical trial • Phase I • NSCLC, PDAC and colon cancer • Good safety up to 10 mg/kg • Significant effect on relevant biomarkers (IL-6, CRP) • 9 patients had stable disease up to 6 months • Phase IIa • FPI Jan 2019 – results early 2020 • NSCLC and PDAC • Monotherapy • Combination wit
Slide 10: Extensive Biomarker program
Extensive Biomarker program Phase II Phase I Purposes: • Generate clinical proof of concept • Identification of patients most likely to respond. 10
Slide 11: IL1RAP found in several cancer forms with high medical need
IL1RAP found in several cancer forms with high medical need • Cantargia founded based on: • Discovery of IL1RAP on cancer cells • Antibodies against IL1RAP - antitumor effects • Patents on antibody therapy against IL1RAP • Primary indications are NSCLC and pancreatic cancer • Biomarker studies ongoi
Slide 12: Two major preclinical findings during 2018 - new opportunities
Two major preclinical findings during 2018 - new opportunities Synergisitic effects with chemotherapy combination • Stronger antitumor effects • Counteracts chemotherapy toxicity Binding to immune cells in tumor microenvironment • Antimetastatic effects • Counteract immune suppression 12
Slide 13: Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine
Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine 10 mice per group NSCLC PDX • CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin) • CAN04 counteracts toxicity from platinum compounds Synergy with chemotherapy in line with current devel
Slide 14: CAN04 attacks several cell types in the tumor
CAN04 attacks several cell types in the tumor CAN04 is relevant to several parts of cancer progression 14
Slide 15: Identification of additional opportunities
Identification of additional opportunities Findings from CANTOS trial (Novartis’ canakinumab) CANCER - decreased risk of death (high dose) Lung cancer 77 % P=0.0002 Non-lung cancer 37 % P=0.06 INFLAMMATORY DISEASE - decreased incidence (all doses) Arthritis 32% p<0.0001 Ostheoartritis 28% P=0.0005 G
Slide 16: IL1RAP platform to treat serious diseases
IL1RAP platform to treat serious diseases • Three different systems signal through IL1RAP • These systems contribute to various inflammatory diseases • Can be blocked by Cantargia’s antibodies against IL1RAP Cantargia partnership with Panorama Res Inc (Sunnyvale, CA) Selection of clinical candidate
Slide 17: Significant value inflection points ahead
Significant value inflection points 2019 - ahead of CANFOUR results • US regulatory and clinical strategy • ASCO oral presentation of phase I data • Clinical progress and initial phase IIa results • Preclinical progress (immuno-oncology effects, combinations etc) • CANxx progress • US clinical trial
Slide 18: Production agreement with Patheon
Production agreement with Patheon • Complements the current agreement with Celonic AG (formerly Glycotope Biotechnology GmbH) • Patheon will scale up the process to 2000 litres before next production campaign of clinical material. • Patheon has manufacturing facilities in both Europe and USA Strateg
Slide 19: Cantargia in brief
Cantargia in brief Current owners (April 30, 2019) • Specialized in antibody therapy/immunology/oncology Sunstone 8.2% • Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020 Alecta 6.6% • Platform around IL1RAP, lead candidate for autoimm
Slide 20: Thank you for your attention!
Thank you for your attention! www.cantargia.com 20